About: Repurpose Open Data to Discover Therapeutics for COVID-19 Using Deep Learning

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Repurpose Open Data to Discover Therapeutics for COVID-19 Using Deep Learning Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Repurpose Open Data to Discover Therapeutics for COVID-19 Using Deep Learning
Creator	Zhang, Zheng Cheng, Feixiong Hou, Yuan Zhou, Yadi Karypis, George Song, Xiang Li, Kenli Ma, Tengfei Pan, Xiaoqin Zeng, Xiangxiang
Source	Medline; PMC
abstract	[Image: see text] There have been more than 2.2 million confirmed cases and over 120 000 deaths from the human coronavirus disease 2019 (COVID-19) pandemic, caused by the novel severe acute respiratory syndrome coronavirus (SARS-CoV-2), in the United States alone. However, there is currently a lack of proven effective medications against COVID-19. Drug repurposing offers a promising route for the development of prevention and treatment strategies for COVID-19. This study reports an integrative, network-based deep-learning methodology to identify repurposable drugs for COVID-19 (termed CoV-KGE). Specifically, we built a comprehensive knowledge graph that includes 15 million edges across 39 types of relationships connecting drugs, diseases, proteins/genes, pathways, and expression from a large scientific corpus of 24 million PubMed publications. Using Amazon’s AWS computing resources and a network-based, deep-learning framework, we identified 41 repurposable drugs (including dexamethasone, indomethacin, niclosamide, and toremifene) whose therapeutic associations with COVID-19 were validated by transcriptomic and proteomics data in SARS-CoV-2-infected human cells and data from ongoing clinical trials. Whereas this study by no means recommends specific drugs, it demonstrates a powerful deep-learning methodology to prioritize existing drugs for further investigation, which holds the potential to accelerate therapeutic development for COVID-19.
has issue date	2020-07-12(xsd:dateTime)
bibo:doi	10.1021/acs.jproteome.0c00316
bibo:pmid	32654489
has license	no-cc
sha1sum (hex)	a4ce5b42f3e41611b3977a58e667668efc53a627
schema:url	https://doi.org/10.1021/acs.jproteome.0c00316
resource representing a document's title	Repurpose Open Data to Discover Therapeutics for COVID-19 Using Deep Learning
has PubMed Central identifier	PMC7384389
has PubMed identifier	32654489
schema:publication	J Proteome Res
resource representing a document's body	covid:a4ce5b42f3e41611b3977a58e667668efc53a627#body_text
is schema:about of	named entity 'integrative' named entity 'knowledge graph' named entity 'human cells' named entity 'deep-learning' named entity 'comprehensive' named entity 'methodology' named entity 'SARS-CoV' named entity 'COVID-19' named entity 'HUMAN CORONAVIRUS' named entity 'GRAPH' named entity '2.2' named entity 'EFFECTIVE' named entity 'HAVE' named entity 'NETWORK' named entity 'RESOURCES' named entity 'COMPREHENSIVE' named entity 'PROTEOMICS' named entity 'SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS' named entity 'REPORTS' named entity 'PATHWAYS' named entity 'TO IDENTIFY' named entity 'IDENTIFIED' named entity 'prevention' named entity 'coronavirus disease 2019' named entity 'connecting' named entity 'termed' named entity 'clinical trials' named entity 'PubMed' named entity 'associations' named entity 'medications' named entity 'therapeutic' named entity 'proven' named entity 'niclosamide' named entity 'PubMed' named entity 'dexamethasone' named entity 'severe acute respiratory syndrome coronavirus' named entity 'coronavirus disease 2019' named entity 'Deep Learning' named entity 'COVID-19' named entity 'antiviral agents' named entity 'indomethacin' named entity 'hydroxychloroquine' named entity 'EUAs' named entity 'U.S. FDA' named entity 'SARS-CoV-2' named entity 'COVID' named entity 'melatonin' named entity 'viral replication' named entity 'melatonin' named entity 'prostate cancer' named entity 'Amazon' named entity 'toremifene' named entity 'Toremifene' named entity 'clinical trials' named entity 'suramin' named entity 'animal studies' named entity 'SERMs' named entity 'cytokine storm' named entity 'circadian rhythm' named entity 'human cell lines' named entity 'SARS' named entity 'SARS-CoV-2' named entity 'hydroxychloroquine' named entity 'PubMed' named entity 'antimalarial drugs' named entity 'ClinicalTrials.gov' named entity 'human cell lines' named entity 'clinical trial' named entity 'COVID-19' named entity 'proteomics' named entity 'vector space' named entity 'COVID'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software